Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 September 2021 | Story Leonie Bolleurs | Photo Supplied
Prince Matova, a PhD student in the Department of Plant Sciences, has been working on breeding a maize that can resist the fall armyworm (FAW) – a maize-eating pest. Later in September, he will receive the Young Scientist Award from the Plant Mutation Breeding Division of the International Atomic Energy Agency (IAEA) and the Food and Agriculture Organisation of the United Nations (FAO).

Prince Matova, a PhD student in Plant Breeding at the University of the Free State (UFS), received the Young Scientist Award from the Joint Food and Agriculture Organisation of the United Nations (FAO)/International Atomic Energy Agency (IAEA) Division of Nuclear Techniques in Food and Agriculture for excellence in plant mutation breeding.

The IAEA Director-General, Mr Rafael Mariano Grossi, will officially announce the award at the 65th regular session of the IAEA General Conference that will take place later in September this year.

The award is given to scientists younger than 40, who have made a significant contribution and impact in the field of mutation breeding.

Matova, a researcher, research and agronomy manager, and maize and legumes breeder at Mukushi Seeds (Pvt) Ltd in Harare, Zimbabwe, says: “People have seen the little work that I have done, and they were happy with it. That makes me happy too.”

Other contributions

In the ten years collaborating with the IAEA, practising mutation breeding, Matova – who believes innovative thinking and self-motivation to be contributing factors to a successful scientist – has also been recognised for other outstanding contributions. These include the release of a cowpea mutant variety in 2017 and its wide dissemination across Zimbabwe, as well as the modernisation of the maize and cowpea national breeding programmes. He has also contributed two publications and appeared twice at IAEA Plant Mutation Breeding symposia. Furthermore, Matova has trained other scientists and fellows across Africa and collaborated with centres of excellence in plant breeding, research, and development.

Growing up, he never guessed that he would one day become an agricultural scientist. Matova was, however, very good at biology and believes that this is one of the reasons why he ended up in crop science. “I am enjoying every moment of it. I love innovativeness and inventions and I view hybrid maize variety development as the greatest innovation in plant breeding. Working for Mukushi Seeds is inspiring; I have a young and dedicated team and the environment allows me to explore my full potential.”

“I feel science solves problems and every day as I do my breeding work, I have this desire to achieve greatness by developing a super maize hybrid,” he says.

Displaying excellence

For the past three to four years, Matova has been working to breed maize varieties that can resist fall armyworm (FAW) – a maize-eating pest. He says the pest has caused significant maize crop yield and economic losses across Africa.

More than 300 million smallholder farmers across sub-Saharan Africa rely on maize for food and livelihoods. “These farmers have limited capacities to control the pest. They are using insecticides, which we have seen to effectively provide immediate control of the pest.” However, these pesticides have environmental and health issues. “It is against this background that we, as plant breeders, felt it was important to develop varieties that are resistant to the pest. It is a more environmentally friendly, less expensive, and more sustainable solution,” explains Matova.
In his research, he evaluated the breeding potential of exotic FAW-resistant donor lines with local lines. He also investigated the resistance response and stability of local cultivars and inbred lines against FAW. 

While working at the Zimbabwean Department of Research and Specialist Services (DR&SS), Matova collaborated with the International Maize and Wheat Improvement Center (CIMMYT), the University of Zimbabwe, the UFS, and the IAEA to look into the possibility of using mutation breeding in maize crop improvement, with the intention to enhance FAW-resistance in maize genotypes.

He introgressed FAW resistance into the elite breeding materials at both DR&SS and Mukushi Seeds, where he is currently working. Matova believes that although FAW resistance is currently a nice-to-have trait, going forward, all maize varieties released should have a baseline resistance to FAW.

Ultimately, his work generated important information that can guide research and maize breeding for FAW resistance in Southern Africa. All this information is free for researchers to use for the betterment of Africa and the world.

Inspired by greatness

There are a number of people in the industry and academia who have inspired Matova. The list includes Dr Cosmos Magorokosho (CIMMYT), Prof Hussein Shimelis (University of KwaZulu-Natal), Dr Fatma Sarsu (IAEA), Dr Marilyn Warburton (Agricultural Research Service in the United States Department of Agriculture), Dr Amsal Terekegne (ZAMSEED), and Dr John MacRobert (Mukushi Seeds). They all contributed in one way or another to influence Matova in a positive way towards becoming the passionate scientist he is today.

Besides this list of prominent names, Matova says that he was more recently also motivated and encouraged by his PhD supervisor and mentor, Prof Maryke Labuschagne, Professor in Plant Sciences at the UFS. “She is a very special person doing a wonderful job. Prof Labuschagne is kind, thorough, hardworking, and a good mentor,” he states.

Prof Labuschagne is very proud of Matova for receiving this award. “He has been working really hard, and this is a wonderful recognition of the time and effort that he has invested in his research,” she says.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept